Yazji Salim 4

Accession 0001209191-23-052022

CIK 0001260990other

View on SEC.gov Company Profile

Filed

Oct 3, 8:00 PM ET

Accepted

Oct 4, 5:01 PM ET

Size

25.3 KB

Accession

0001209191-23-052022

Insider Transaction Report

Form 4

Period: 2023-10-02

Oncternal Therapeutics, Inc.ONCT

Yazji Salim

Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option
2023-10-02−210,000→ 0 total
Exercise: $0.96Exp: 2033-02-21→ Common Stock (210,000 underlying)
Award
Stock Option
2023-10-02+55,000→ 55,000 total
Exercise: $0.31Exp: 2032-07-28→ Common Stock (55,000 underlying)
Award
Stock Option
2023-10-02+70,600→ 70,600 total
Exercise: $0.31Exp: 2031-05-17→ Common Stock (70,600 underlying)
Award
Stock Option
2023-10-02+354,400→ 354,400 total
Exercise: $0.31Exp: 2031-04-29→ Common Stock (354,400 underlying)
Disposition to Issuer
Stock Option
2023-10-02−354,400→ 0 total
Exercise: $5.30Exp: 2031-04-29→ Common Stock (354,400 underlying)
Award
Stock Option
2023-10-02+92,075→ 92,075 total
Exercise: $0.31Exp: 2032-01-20→ Common Stock (92,075 underlying)
Award
Stock Option
2023-10-02+210,000→ 210,000 total
Exercise: $0.31Exp: 2033-02-21→ Common Stock (210,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−92,075→ 0 total
Exercise: $1.94Exp: 2032-01-20→ Common Stock (92,075 underlying)
Disposition to Issuer
Stock Option
2023-10-02−55,000→ 0 total
Exercise: $1.04Exp: 2032-07-28→ Common Stock (55,000 underlying)

Footnotes (8)

[F1]25% of the shares subject to the option ("Option Shares") vested on May 17, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F2]On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged.
[F3]25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F4]50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).
[F5]25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F6]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised.
[F7]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised.
[F8]25% of the Option Shares vested on May 17, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. The option may not be exercised if recipient's employment or service terminates prior to October 2, 2024 other than as a result of a Qualifying Termination. All of the Option Shares vest and become exercisable in the event of a Change in Control.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Oncternal Therapeutics, Inc.

CIK 0001260990

→

Entity typeother

Related Parties

filerCIK 0001864486

Filing Metadata

Form type: 4
Filed: Oct 3, 8:00 PM ET
Accepted: Oct 4, 5:01 PM ET
Size: 25.3 KB

View on SEC.gov